InfuSystem (NYSEAMERICAN:INFU) Lifted to “Strong-Buy” at StockNews.com

StockNews.com upgraded shares of InfuSystem (NYSEAMERICAN:INFU) from a buy rating to a strong-buy rating in a report issued on Monday.

Separately, Lake Street Capital upgraded InfuSystem to a strong-buy rating in a research note on Thursday, May 9th.

InfuSystem Price Performance

Shares of NYSEAMERICAN INFU opened at $6.74 on Monday. InfuSystem has a 1 year low of $5.74 and a 1 year high of $11.18. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.87 and a quick ratio of 1.51. The stock has a market cap of $143.56 million, a P/E ratio of -674,000.00 and a beta of 1.44.

InfuSystem (NYSEAMERICAN:INFU) last posted its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). InfuSystem had a net margin of 0.07% and a return on equity of 0.16%. The company had revenue of $33.70 million for the quarter.

Insider Transactions at InfuSystem

In related news, Director Paul Andrew Gendron acquired 5,000 shares of the firm’s stock in a transaction dated Monday, May 20th. The shares were purchased at an average price of $6.54 per share, with a total value of $32,700.00. Following the completion of the purchase, the director now directly owns 65,000 shares of the company’s stock, valued at $425,100. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, Director Ralph F. Boyd, Jr. bought 4,000 shares of the company’s stock in a transaction that occurred on Thursday, May 23rd. The stock was bought at an average price of $7.13 per share, with a total value of $28,520.00. Following the acquisition, the director now owns 6,000 shares of the company’s stock, valued at approximately $42,780. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Paul Andrew Gendron purchased 5,000 shares of the firm’s stock in a transaction on Monday, May 20th. The shares were acquired at an average cost of $6.54 per share, for a total transaction of $32,700.00. Following the completion of the acquisition, the director now owns 65,000 shares of the company’s stock, valued at $425,100. The disclosure for this purchase can be found here. Insiders purchased 13,000 shares of company stock worth $87,300 in the last three months. Corporate insiders own 10.20% of the company’s stock.

Hedge Funds Weigh In On InfuSystem

Several hedge funds have recently modified their holdings of INFU. Rhumbline Advisers lifted its position in shares of InfuSystem by 13.8% in the second quarter. Rhumbline Advisers now owns 17,658 shares of the medical instruments supplier’s stock worth $121,000 after buying an additional 2,145 shares in the last quarter. Marshall Wace LLP bought a new position in shares of InfuSystem during the 2nd quarter valued at approximately $131,000. Oppenheimer Asset Management Inc. grew its holdings in shares of InfuSystem by 52.1% in the second quarter. Oppenheimer Asset Management Inc. now owns 26,042 shares of the medical instruments supplier’s stock valued at $178,000 after purchasing an additional 8,917 shares in the last quarter. Panagora Asset Management Inc. bought a new stake in InfuSystem in the second quarter worth $208,000. Finally, ARS Investment Partners LLC raised its stake in InfuSystem by 11.4% during the second quarter. ARS Investment Partners LLC now owns 33,510 shares of the medical instruments supplier’s stock valued at $229,000 after purchasing an additional 3,422 shares in the last quarter. Hedge funds and other institutional investors own 71.13% of the company’s stock.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.